David A. Siegel Harmony Biosciences Holdings, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 92,700 shares of HRMY stock, worth $2.41 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
92,700
Previous 140,800
34.16%
Holding current value
$2.41 Million
Previous $4.67 Million
37.32%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding HRMY
# of Institutions
287Shares Held
46.3MCall Options Held
316KPut Options Held
69.9K-
Valor Management LLC Chicago, IL6.62MShares$172 Million88.32% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$151 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$133 Million0.0% of portfolio
-
State Street Corp Boston, MA1.63MShares$42.3 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.58MShares$41.1 Million0.01% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $1.54B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...